# Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study

> **NCT04401059** · PHASE4 · UNKNOWN · sponsor: **Tian Xie** · enrollment: 744 (estimated)

## Conditions studied

- Carcinoma
- Non-Small-Cell Lung Cancer
- Adenocarcinoma

## Interventions

- **DRUG:** Elemene plus first or third generation EGFR-TKIs
- **DRUG:** First or third generation EGFR-TKIs

## Key facts

- **NCT ID:** NCT04401059
- **Lead sponsor:** Tian Xie
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-09
- **Primary completion:** 2025-09-30
- **Final completion:** 2026-03-30
- **Target enrollment:** 744 (ESTIMATED)
- **Last updated:** 2023-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04401059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04401059, "Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04401059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*